Zinc Oxide VS MEBO

Not Applicable

Recruiting

• Conditions: Pressure Injury; Pressure Injury Stage 2; Bedsore; Pressure Ulcers Stage II; Pressure Ulcer, Buttock
• Interventions: Drug: zinc oxide; Drug: MEBO Wound Ointment

• Registration Number: NCT07193849
• Lead Sponsor: King Abdullah Medical City

Brief Summary

randomize control trial to evaluate the efficacy of using zinc oxide versus moist exposed wound ointment in treatment of second stage pressure ulcer.

Detailed Description

In this study the subject will be randomized using electronic randomization 1:1 ratio. The randomization list was generated electronically through R using the Random Allocation Rule. The data will be collected using Assessment sheet of patient with second stage pressure ulcer tool. Patients will equally be allocated into 2 groups randomly. The zinc oxide group will receive topical zinc oxide twice every 12 hours daily and patients in the MEBO group will receive topical MEBO ointment twice every 12 daily. Patient will be examined daily till complete healing for the pressure ulcer and maximum one month. The Bates-Jensen Wound Assessment Tool (BWAT) will be used to evaluate wound healing. It is a validated wound assessment tool which is used in many healthcare settings for wound assessment

Study Timeline

• Study Start: 2023-12-31
• Study First Submitted: 2025-06-29
• Status Verified: 2025-09
• Study First Submitted QC: 2025-09-22
• Last Update Submitted: 2025-09-22
• Study First Posted: 2025-09-26
• Last Update Posted: 2025-09-26
• Primary Completion: 2025-12-31
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

• Willing to participate.
• KAMC cases in medical ward, neuroscience ward, and intensive care unit.
• Newly cases diagnosed with second stage pressure ulcer according to the European pressure ulcer advisory panel/national pressure ulcer advisory panel (NPUAP) guidelines.

Exclusion Criteria

• Not consenting to participate
• Patients with suspected hypersensitivity reactions to any of the topical formulation's ingredients.
• Either a category III or IV pressure ulcer.
• Evidence of deep tissue injury (exudative drainage, purple or maroon localized area of discolored intact skin or blood-filled blister due to pressure damage).
• Signs of wound infection (pus draining from the ulcer, a foul-smelling odour, tenderness, heat and increased redness in the surrounding skin and fever).
• Patients who undertaking other therapies that could affect healing, such as corticosteroids, radiation therapy, or chemotherapy for cancer.
• Heavy smoking (more than 20 cigarettes a day).
• Concomitant chronic disease (e.g., diabetes mellitus or frank vascular disease such as Buerger's disease).
• Patients who unable to continue the study because of death, discharge, or change in the care setting.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
The zinc oxide group	zinc oxide	The zinc oxide group will receive topical zinc oxide twice every 12 hours daily
MEBO group	MEBO Wound Ointment	patients in the MEBO group will receive topical MEBO ointment twice every 12 daily

Primary Outcome Measures

Name	Time	Method
Wound healing	30 days	Wound healing will be assessed by using Bates-Jensen Wound Assessment Tool (BWAT) daily for both treatments.; (BWAT) consists of 13 items to evaluate wound size, type and depth, Each item is graded on a scale of 1 to 5, where a score of 1 indicates progress toward healing while a score of 5 indicates the absence of healing or wound deterioration. Cumulative BWAT scores vary from 13 to 65

Secondary Outcome Measures

Name	Time	Method
Recovery time	30 days	The duration of treatment will be record at the assessment sheet so Recovery time will be determined from this sheet.

Trial Locations

Locations (1)

King Abdulla Medical City in Holy capital; 🇸🇦 Makkah al Mukarramah, Western Reagan, Saudi Arabia